Genocea Biosciences Agreement with U.S. Military to Develop Malaria vaccine

Cambridge: Genocea Biosciences, a leading vaccine discovery and development company, announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC). NMRC will collaborate with Genocea to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria. Genocea and NMRC will leverage their expertise to identify novel malaria vaccine candidate antigens and move promising antigens through preclinical development. Genocea will apply its technology to the rapid.

Identification of novel T-cell antigens from a proteomic screen of the P.falciparum organism, and NMRC will share material as well as their extensive experience developing subunit malaria vaccines. This work is funded by a $2.7 million award that was granted to Genocea from the U.S. Army Medical Research and Material Command (USAMRMC) for rapid T-cell screens of a P.falciparum proteomic library